Antiviral therapy to prevent carcinogenesis
의약학 > 내과학
( Mark Thursz )
KASL 2012년, 제2012권 157(총1쪽)
27405449.pdf [무료 PDF 뷰어 다운로드]
  • ※ 본 자료는 참고용 논문으로 수정 및 텍스트 복사가 되지 않습니다.
  • 구매가격
    30원 (구매자료 3% 적립)
    이메일 발송  스크랩 하기
    자료 다운로드  네이버 로그인
    Whenever treatment decisions are made for patients with chronic viral hepatitis the clinician should keep in mind the therapeutic goals that they are trying to achieve. As trials of antiviral therapy are invariably based on relatively short term surrogate endpoints we tend to lose sight of the long term goals; suppression of viral replication is encouraging but can we extrapolate this endpoint to the avoidance of premature mortality which is our ultimate aim. In chronic hepatitis B virus (HBV) infection the development of potent nucleos (t) ide analogues (NA) has revolutionised the treatment of patients with chronic HBV infection. These agents allow us to suppress viral replication very effectively with minimal side effects. We have also recently seen that therapy can result in HBeAg to anti HBe seroconversion and, in patients who are HBeAg positive, prolonged therapy may result in HBsAg loss. A series of histologically based studies now show us that NAs will reverse fibrosis and even ``reverse`` cirrhosis. However, in clinical practice we still see the development of hepatocellular carcinoma (HCC) in patients where viral replication has been effectively suppressed. Does this mean that the NAs do not influence the development of HCC? Only one placebo controlled trial provides us with evidence that Lamivudine reduces the risk of HCC. For ethical reasons this can never be repeated and as a result other evidence of benefit is circumstantial. Nevertheless it is probably safe to conclude that NA treatment reduces the risk of HCC but does not eliminate it. The exact magnitude of the reduction is a little hard to estimate but probably depends on the stage of disease and the age of the patient at the time that treatment was initiated. In chronic hepatitis C virus (HCV) infection the situation is similarly confused. It is now clear that elimination of the virus (sustained virological response) is associated with improvement of liver fibrosis and a reduction in the risk of developing HCC. However, in a proportion of patients with cirrhosis at the time they started treatment there is little resolution of the fibrosis and the risk of HCC persists after viral elimination. The important clinical point is that whilst virological control is important and will reduce risk of HCC it is still vital to maintain patients under surveillance.
    사업자등록번호 220-87-87785 대표.신현웅 주소.서울시 서초구 방배로10길 18, 402호 대표전화.070-8809-9397
    개인정보책임자.박정아 통신판매업신고번호 제2017-서울서초-1765호 이메일
    copyright (c) 2009 happynlife. steel All reserved.